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Recently an early onset lethal encephalopathy has been described in relation to mutations of NFU1, one of the
genes involved in iron-sulfur cluster metabolism. We report a new NFU1 mutated patient presenting with a milder
phenotype characterized by a later onset, a slowly progressive spastic paraparesis with relapsing-remitting episodes,
mild cognitive impairment and a long survival. The early white matter abnormalities observed on MRI was combined
with a mixed sensory-motor neuropathy in the third decade. Our case clearly suggests the importance of considering
NFU1 mutation in slowly evolving leukoencephalopathy with high glycine concentration.
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Mutations of NFU1, one of the genes involved in iron-
sulfur cluster metabolism have been recently reported in
14 patients with an early onset and rapidly fatal enceph-
alopathy and/or severe pulmonary hypertension [1-4].
The patients reported died before the age of 15 months
[1-3] except for one who was still alive, but severely
affected, at the age of 2.5 years [4]. The MRI performed
only in this last patient shown white matter abnormalities
with cystic degeneration in the periventricular region
and in corpus callosum [4]. The brain autopsy analysis
performed in 7 patients, demonstrated also white matter
demyelination, vacuolization and astrogliosis. We report a
new NFU1 mutated patient with a significantly milder
phenotype than previously reported.
Clinical data
The patient was the second born child of unrelated
healthy parents. Pregnancy and delivery were uneventful.
Psychomotor development was initially normal. At the
age of 18 months, concomitantly to an intercurrent viral
illness, he lost the ability to walk, stand, sit, grip, he par-
tially lost head control and spastic tetraparesis appeared.* Correspondence: odile.boespflug-tanguy@rdb.aphp.fr
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unless otherwise stated.After this acute episode he partially recovered: one year
later he was able to sit again and to stand alone but he
never regained the ability to walk. He was first evaluated
in our department at 17 years of age. Neurological exam-
ination showed a spastic paraparesis with mild cognitive
impairment. Electrophysiological studies performed at
18 years of age (BAEP, VEP, ERG, SEP, EMG, NCV, EEG)
were normal. Progressive scoliosis required spine surgery
at 18 years of age. At the age of 24 years he subacutely
developed flaccid paraplegia with superficial and deep
hypoesthesia, EMG and NCV revealed the presence of a
severe mixed motor-sensory neuropathy on lower limbs.
Lipoic acid treatment (200 mg/day) has been introduced
at the age of 28, without significant improvement. The pa-
tient now aged 30 years remains stable. However, during
the last year, he developed an acute oedema of the lower
limbs related to severe bladder dysfunctions requiring a
urinary catheter.Radiological findings
MRI performed at 3, 7, 16, 19, 24, 28 years of age revealed
the presence of white matter abnormalities involving the
periventricular regions and the posterior part of the
corpus callosum which was also severely atrophic. Single
voxel proton MR spectroscopy of the abnormal lobar
white matter showed a severe reduction of the N-acetyl
aspartate (NAA) peak, an increase in the choline (Cho)l. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
Figure 1 Radiological findings. MRI (A-D) and H-MRS (E) of patient 1 at 28 years of age. FLAIR (A-C) and T1 (D) sequences. MRI revealed the
presence of white matter abnormalities hyperintense on FLAIR sequences, involving the periventricular regions (A-C) and the posterior part of
corpus callosum (A) which was also severely atrophic (D). H-MRS (TE = 136 milliseconds) of the abnormal lobar white matter showed a severe
reduction of the N-acetyl aspartate (NAA) peak, an increase of the choline (Cho) peak and a mild doublet inverted peak (white arrow) consistent
with elevated lactate (lac).
Table 1 Biochemical findings
Glycine Plasma (μM) Urines (μM) CSF (μM)
530 (181–293) 3077 (43–173) 43 (1–16)
Redox status Lactate (mM) Pyruvate (mM) Pyruvate/
Lactate
Fasting 1 (0.6-1.9) 94 (50–140) 10, 5 (<10)




CI 9 (9–13) NA
CII 6 (20–42) 4, 11-19
CIII 67 (61–132) 60 (33–67)
CIV 59 (81–171) 51 (41–81)
PDHc NA 98 (1372–3104)
CS 34 (76–140) 42 (31–65)
CIV/CS 1.74 (1.1-1.9) 1.21 (0.9-1.6)
CIV/CII 9.83 (3.4-6.1) 12.75 (2.7-5.3)
CIV/CI 6.56 (10.5-20.9) NA
CII/CS 0.18 (0.25-0.41) 0.10 (0.24-0.38)
AKGDH 5.4 (4–9) 0.3 (4–9)
Concentration of lactate, pyruvate and glycine in body fluids and mitochondrial
enzymatic activities at 27 years of age. Abnormal concentrations are highlighted
in bold. Normal values in brackets. CSF = cerebrospinal fluid, CS = citrate synthase,
CI = complex I, CII = complex II, CIV = complex IV, PDHc = pyruvate
dehydrogenase complex (PDHc) and AKGDH = α-ketoglutarate dehydrogenase.
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tate (Figure 1). MRI abnormalities remained globally
stable during the long radiological follow-up.
Laboratory investigations
No documentation concerning laboratory investigations
performed before referring to our Institute is still avail-
able. Aminoacid chromatographies on urine, plasma and
CSF performed at 27 years of age revealed high concen-
tration of glycine (Table 1). Redox status evaluations at
22 and 27 years of age showed a mild elevation of lactic
and pyruvic acids after meal (Table 1). Activities of the
respiratory chain complexes (mainly complex II) were
low in muscle and fibroblasts as well as the pyruvate de-
hydrogenase complex and the α-ketoglutarate dehydro-
genase in fibroblasts (Table 1).
Molecular analysis of NFU1 revealed the presence of one
novel mutation (c.146delC, p.Pro49LeufsX8) predicted to
be damaging (Align DGVD, Polyphen-2, SIFT, MutationTa-
ster) inherited from the mother and a previously reported
missense mutation (c.565G >A, p.Gly189Arg) [4] inherited
from the father.
Discussion
Iron-sulfur clusters (Fe-S) are essential components of
many mitochondrial, nuclear and cytosolic proteins [5].
We described a new patient affected by a disorder of
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tations of the NFU1 gene. All patients so far described
presented a clinical picture dominated by an early onset
severe encephalopathy and/or a severe pulmonary hyper-
tension that lead in both cases to early death [1-4]. In
sharp contrast, our patient presented a milder progressive
leucoencephalopathy with a later age of onset (18 months
of age) characterized by stress induced deterioration
followed by partial recover, as usually observed in mito-
chondrial diseases [6]. No signs of pulmonary hyperten-
sion were ever found. The patient reached an age of
30 years with relatively stable neurological conditions. A
subacute demyelinating mixed motor sensory neuropathy,
never yet reported in NFU1 mutations, appeared in the
third decade. Peripheral neuropathy is a typical feature in
PDHA1 deficiency [7]. On our patient, NFU1 mutations
result in a severe PDH defect demonstrated in fibroblasts.
Moreover, differently to what is reported to date, our
patient’s lactate and pyruvate levels were only high post-
prandially and the lactate/pyruvate ratio was normal.
These data suggest a PDH deficiency more than an oxida-
tive phosphorylation deficiency [1-4]. For this reason we
suggest the possibility that the neuropathy in this patient
may be related to the severe PDH deficiency.
The reason for the clinical and biological differences
between our patient and those previously described is
not clear. We can observe that patients reported to date
were all homozygous either for the same null mutation
or for the same missense mutation with only two patient
heterozygotes for two different missense mutations [3,4].
Our patient was found to be compound heterozygote for
a null and a missense mutation, one never reported so
far. We could speculate that this genetic situation and
probably some unknown epigenetic factors could differ-
ently modulate the final phenotype.
Our case clearly suggests the importance of considering
NFU1 mutation not only in early onset leukoencephalopa-
thy or in presence of a severe pulmonary hypertension but
also in a more slowly evolving and later onset leukoence-
phalopathy with sometimes acute phases of deterioration.
High concentration of glycine in body fluids is a key diag-
nostic marker.Abbreviations
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